Fig 1. Comparison of CD8⁺ T cell subset among NC, TCMR and LTGS groups.

(A) PBMCs were stained with anti-CD8–APC, anti-CCR7 strepavidin, anti-CD45RA FITC, anti-CD28-PE and anti-CD57-FITC antibodies. CD8⁺ T cells were gated for further analysis. (B-I) Proportion (%) of (B) Lymphocytes, (C) CD8⁺ T cells/lymphocytes, (D) CCR7⁺CD45RA⁺CD8⁺ T cells, (E) CCR7⁺CD45RA^-CD8⁺ T cells, (F) CCR7⁺CD8⁺ T cells, (G) CCR7^-CD45RA^-CD8⁺ T cells, (H) CCR7^-CD45RA⁺CD8⁺ T cells, (I) CD28^null CD57⁺CD8⁺ T cells in each patient group. *p < 0.05 vs. NC, ^†p < 0.05 vs. LTGS. Abbreviations; LTGS, long-term graft survival; NC, Normal control; TCMR, T cell mediated rejection.